Pfizer (PFE) Announces FDA Breakthrough Therapy Designation for TRUMENBA for Prevention of Invasive Meningococcal B Disease in Children Ages 1 to 9 Years
Tweet Send to a Friend
Pfizer Inc. (NYSE: PFE) today announced that TRUMENBA® (Meningococcal Group B Vaccine) received Breakthrough Therapy designation from the U.S. Food ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
